Cancer imaging : the official publication of the International Cancer Imaging Society · 2026
Long-term prognostic value of 18F-FLT PET/CT versus 18F-FDG PET/CT in locally advanced oesophageal squamous cell carcinoma: a prospective study.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gao Wenyan, Peng Jingwen, Chen Xue, Wang Yi, Zhi Shunji, Wu Lei, Wan Gang, Cheng Zhuzhong, Wang Qifeng, Zhang Wei
Аннотация
BACKGROUND: Accurate prognostication in locally advanced oesophageal squamous cell carcinoma (LA-ESCC) remains a significant clinical challenge. This prospective study aimed to compare the predictive value of fluorine-18 fluorodeoxyglucose (18F-FDG) and fluorine-18 fluorothymidine (18F-FLT) positron emission tomography/computed tomography (PET/CT) regarding long-term clinical outcomes.
METHODS: Between June 2018 and July 2019, 31 patients with LA-ESCC were prospectively enrolled and underwent both 18F-FDG and 18F-FLT PET/CT scans prior to or during initial therapy. Quantitative parameters, including maximum standardized uptake value (SUV max), minimum SUV (SUV min), mean SUV (SUV mean), tumour metabolic volume (MTV), total lesion glycolysis (TLG), and total lesion 18F-FLT expression (TLT), were measured for primary tumours and regional lymph nodes. Progression-free survival (PFS) and overall survival (OS) were analysed using Cox univariate regression, receiver operating characteristic (ROC) curve analysis, and Kaplan-Meier survival estimates.
RESULTS: In 18F-FLT PET/CT, primary tumour parameters (SUV max, SUV mean, TLT) and all lymph node parameters significantly distinguished between favourable and poor PFS groups (all P <0.05). Primary tumour SUV max, SUV mean, and all lymph node parameters demonstrated a negative correlation with both PFS and OS. Specifically, lymph node SUV max (PFS: hazard ratio (HR)=1.65, 95% confidence interval (CI):1.23-2.19, P =0.002; OS: HR = 1.81, 95% CI:1.29-2.55, P <0.001) and SUV mean showed strong predictive value. In contrast, for 18F-FDG PET/CT, only lymph node MTV differed significantly between PFS groups (P =0.03), with no parameters showing significant prognostic correlation. ROC analysis indicated that 18F-FLT lymph node SUV max and SUV mean yielded the highest predictive accuracy for PFS (area under the curve (AUC): 83.8% and 84.2%, respectively) and OS (AUC: 79.3% for both).
CONCLUSIONS: 18F-FLT PET/CT may offer superior prognostic value compared to 18F-FDG PET/CT for long-term survival prediction in LA-ESCC. Parameters derived from metastatic lymph nodes, particularly SUV max and SUV mean, may serve as potential biomarkers for poor clinical outcomes, independent of imaging timing.
METHODS: Between June 2018 and July 2019, 31 patients with LA-ESCC were prospectively enrolled and underwent both 18F-FDG and 18F-FLT PET/CT scans prior to or during initial therapy. Quantitative parameters, including maximum standardized uptake value (SUV max), minimum SUV (SUV min), mean SUV (SUV mean), tumour metabolic volume (MTV), total lesion glycolysis (TLG), and total lesion 18F-FLT expression (TLT), were measured for primary tumours and regional lymph nodes. Progression-free survival (PFS) and overall survival (OS) were analysed using Cox univariate regression, receiver operating characteristic (ROC) curve analysis, and Kaplan-Meier survival estimates.
RESULTS: In 18F-FLT PET/CT, primary tumour parameters (SUV max, SUV mean, TLT) and all lymph node parameters significantly distinguished between favourable and poor PFS groups (all P <0.05). Primary tumour SUV max, SUV mean, and all lymph node parameters demonstrated a negative correlation with both PFS and OS. Specifically, lymph node SUV max (PFS: hazard ratio (HR)=1.65, 95% confidence interval (CI):1.23-2.19, P =0.002; OS: HR = 1.81, 95% CI:1.29-2.55, P <0.001) and SUV mean showed strong predictive value. In contrast, for 18F-FDG PET/CT, only lymph node MTV differed significantly between PFS groups (P =0.03), with no parameters showing significant prognostic correlation. ROC analysis indicated that 18F-FLT lymph node SUV max and SUV mean yielded the highest predictive accuracy for PFS (area under the curve (AUC): 83.8% and 84.2%, respectively) and OS (AUC: 79.3% for both).
CONCLUSIONS: 18F-FLT PET/CT may offer superior prognostic value compared to 18F-FDG PET/CT for long-term survival prediction in LA-ESCC. Parameters derived from metastatic lymph nodes, particularly SUV max and SUV mean, may serve as potential biomarkers for poor clinical outcomes, independent of imaging timing.